MiMedx Group

MiMedx Group

Biotechnology
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

$464M

Market Cap • 11/17/2026

2008

(18 years)

Founded

2007

(19 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,2

P/S

1,5

P/EBITDA

—

P/OCF

22,4

P/FCF

24,3

P/E

—

BVPS

1,4

EPS

—

Market Cap

Market Cap

464M

EV

343,3M

EV/Revenue

1,1

EV/EBITDA

-19,8

EV/EBIT

-13,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

3,2%

Total Yield

3,2%

Payout

0%

Retained Earnings

-77,1M

Profitability

Gross Margin

77,3%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

4,8%

Capex/Revenue

0,5%

Capex/D&A

20,7%

Capex/OCF

7,8%

SBC/OCF

23,5%

% PPE

1,8%

% Goodwill

7,3%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

3,2%

CAGR Op. Income 5Y

0,6%

CAGR Net Income 5Y

-8%

CAGR EPS 5Y

-17%

Leverage

N.D./EBITDA

7

Debt/Equity

0%

Current Ratio

4,4

Quick Ratio

3,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium